Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
Gimeno, J.R.; Olivotto, I.; Rodríguez, A.I.; Ho, C.Y.; Fernández, A.; Quiroga, A.; Espinosa, M.A.; Gómez-González, C.; Robledo, M.; Tojal-Sierra, L.; Day, S.M.; Owens, A.; Barriales Villa, Roberto; Larrañaga, J.M.; Rodríguez-Palomares, J.; González-del-Hoyo, M.; Piqueras-Flores, J.; Reza, N.; Chumakova, O.; Ashley, E.A.; Parikh, V.; Wheeler, M.; Jacoby, D.; Pereira, A.C.; Saberi, S.; Helms, A.S.; Villacorta, E.; Gallego-Delgado, M.; de Castro, D.; Domínguez, F.; Ripoll-Vera, T.; Zorio-Grima, E.; Sánchez-Martínez, J.C.; García-Álvarez, A.; Arbelo, E.; Mogollón, M.V.; Fuentes-Cañamero, M.E.; Grande, E.; Peña, C.; Monserrat Iglesias, Lorenzo; Lakdawala, N.K.; Muñoz-Esparza, C.; García-Pinilla, J.M.; Robles-Mezcua, A.; Moreno-Flores, M.V.; Peña, M.L.; Merlo, M.; Cubillo, D.V.; Climent-Payá, V.; Dankovtseva, E.; Rodríguez Vilela, Alejandro; García-Pavía, P.; Casas, G.

Identificadores
Identificadores
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2022Título da revista
ESC Heart Failure
Tipo de contido
Article
Resumo
Aims: To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Methods and results: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). Conclusions: Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución-NoComercial 4.0 Internacional
